Hospira's biosimilar Inflectra comparable to Remicade in IBD treatment

19 February 2015
biosimilars_samples_large

Positive data have been presented today on the use of Hospira's (NYSE: HSP) Inflectra (infliximab), the world's first approved biosimilar monoclonal antibody (MAb), at the European Crohn's and Colitis Organization Inflammatory Bowel Diseases (ECCO-ibd) conference.

Earlier this week, Hospira - currently the subject of a $17 billion agreed acquisition by US pharma giant Pfizer (NYSE: PFE) - announced the launch of Inflectra in major European markets.

Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade (infliximab), from US health care giant Johnson & Johnson (NYSE: JNJ) and Merck & Co (NYSE: MRK; which has marketing rights outside the USA Japan and China), for inducing and maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease (IBD).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars